Novartis, the $33 billion Swiss pharmaceutical company, is opening a pioneering biomedical R&D facility in China. The $100 million plant, scheduled to begin operations in May, will increase the company’s long-term access to the huge Chinese pharmaceutical market and attract top Chinese scientific talent. But CEO Daniel Vasella says there’s more to the story. Novartis, […]